Gabapentin (All indications) updated on 04-22-2025

Atrial septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10033
R36105		 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Atrial septal defect 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 0.48 [0.03;8.37] C
excluded (control group) 		0/365   8/2,997 8 365
ref
S10034
R36128		 Blotière (Controls unexposed NOS) (Other indications), 2019 Atrial septal defect 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.79 [0.05;12.59] C 0/365   3,268/1,875,733 3,268 365
ref
S8491
R35399		 Miškov (Controls unexposed, disease free), 2016 Atrial septal defec during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 765.00 [11.05;52971.87] C
excluded (control group) 		1/2   0/128 1 2
ref
S8492
R35406		 Miškov (Controls unexposed, sick), 2016 Atrial septal defect during pregnancy (anytime or not specified) excluded prospective cohort unexposed, sick Adjustment: No 21.00 [0.27;1646.32] C
excluded (exposition period) 		1/2   0/4 1 2
ref
Total 1 studies 0.79 [0.05;12.59] 3,268 365
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 1 0.79[0.05; 12.59]3,2683650%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS) (Other indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.79[0.05; 12.59]3,268365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.79[0.05; 12.59]3,268365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 Tags Adjustment   - No  - No 0.79[0.05; 12.59]3,268365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 All studiesAll studies 0.79[0.05; 12.59]3,268365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8491, 10033

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.79[0.05; 12.59]3,268365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.48[0.03; 8.37]8365 -NABlotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 10.510.01.0